Elicera Therapeutics Future Growth

Future criteria checks 2/6

Elicera Therapeutics's earnings are forecast to decline at 15.2% per annum while its annual revenue is expected to grow at 57.5% per year. EPS is expected to decline by 19.7% per annum.

Key information

-15.2%

Earnings growth rate

-19.7%

EPS growth rate

Biotechs earnings growth	45.7%
Revenue growth rate	57.5%
Future return on equity	n/a
Analyst coverage	Low
Last updated	17 Oct 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

OM:ELIC - Analysts future estimates and past financials data (SEK Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	32	-33	N/A	N/A	2
12/31/2025	2	-33	-25	-25	2
12/31/2024	6	-29	-30	-30	2
6/30/2024	12	-21	-28	-28	N/A
3/31/2024	13	-20	-22	-22	N/A
12/31/2023	11	-16	-15	-15	N/A
9/30/2023	12	-16	-13	-13	N/A
6/30/2023	4	-18	-4	-4	N/A
3/31/2023	2	-17	-5	-5	N/A
12/31/2022	1	-19	-9	-9	N/A
9/30/2022	1	-18	-15	-15	N/A
6/30/2022	0	-17	-24	-24	N/A
3/31/2022	0	-15	-16	-16	N/A
12/31/2021	0	-13	-14	-14	N/A
9/30/2021	0	-14	-14	-14	N/A
6/30/2021	N/A	-7	-1	-1	N/A
3/31/2021	N/A	-5	-4	-4	N/A
12/31/2020	N/A	-3	-1	-1	N/A
12/31/2019	N/A	0	0	0	N/A
12/31/2018	N/A	0	N/A	N/A	N/A
12/31/2017	N/A	0	N/A	N/A	N/A
12/31/2016	N/A	0	N/A	N/A	N/A
12/31/2015	N/A	0	N/A	N/A	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ELIC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ELIC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ELIC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ELIC's revenue (57.5% per year) is forecast to grow faster than the Swedish market (-0.04% per year).

High Growth Revenue: ELIC's revenue (57.5% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ELIC's Return on Equity is forecast to be high in 3 years time

Elicera Therapeutics Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Recent updates

Elicera Therapeutics Includes the First Patient in the Phase I/II Clinical Study Carma Targeting B-Cell Lymphoma

Elicera Therapeutics AB (publ) Enrolls the Last Patient in the Clinical Phase I/II-Trial with Oncolytic Virus ELC-100

New major risk - Financial position

Elicera Therapeutics Set to Begin First Clinical CAR T-Cell study CARMA

New major risk - Shareholder dilution

Elicera Therapeutics AB (publ), Annual General Meeting, May 16, 2024

New major risk - Financial position

Elicera Therapeutics AB (publ) to Present at the Scientific Conference International Society for Cell & Gene Therapy Meeting 2024 in Vancouver, Canada, May 28 to June 1

Elicera Therapeutics AB (Publ) Receives Conditional Approval from the Medical Products Agency on Its Car T-Cell Clinical Trial Application to Test ELC-301

Elicera Therapeutics Receives Approval to Initiate Clinical Phase I/II-Study Carma with Car T-Cell Therapy ELC-301 in B-Cell Lymphoma

Elicera Therapeutics AB (publ) Co-Founder Receives Grant Totalling 4.8 million SEK from the Swedish Childhood Cancer Fund to Support Car T-Cell Research

Elicera Therapeutics AB (publ) Submits GMP Validation Data to the Swedish Medical Products Agency for the CARMA Study to Supplement the Conditionally Approved Clinical Trial Application

New major risk - Share price stability

Elicera Therapeutics AB (Publ) Announces That Representatives of the Largest Owners Appoints the Nomination Committee Ahead of the Annual General Meeting 2024

Elicera Therapeutics AB (publ) Receives Notice of Allowance for European Patent Protecting the iTANK

New major risk - Financial position

Elicera Therapeutics AB (publ) Submits Clinical Trial Application to Evaluate Its CAR T-Cell Therapy in B-Cell Lymphoma

Elicera Therapeutics AB (publ) Continues Phase I/IIa Study with Oncolytic Virus as Planned, Following Safety Review in Cohort 3

Elicera Therapeutics AB (publ) Announces Positive Clinical Effect in Cancer Trial

Elicera Therapeutics Reports Additional Signals of Clinical Activity in Patients Treated for Neuroendocrine Tumors in the Elc-100 Study At the Oncolytic Virotherapy Summit in Boston

Elicera Therapeutics AB (publ) to Report Fiscal Year 2022 Results on Feb 17, 2023

High number of new and inexperienced directors

Elicera Therapeutics AB (publ) Receives EUR 2.5 Million Funding to Fully Finance Clinical Phase I/II-Trial with its Car T-Cell Therapy, ELC-301

Elicera Therapeutics Successfully Concludes Preclinical Proof-Of-Concept Studies for Oncolytic Virus ELC-201 Confirming the Proposed Mode-Of-Action

High number of new and inexperienced directors

High number of new and inexperienced directors

Elicera Therapeutics AB (publ) Enters into Agreement with Baylor College of Medicine for Contract Manufacturing of Next Generation Oncolytic Virus, ELC-201

Elicera Therapeutics AB (publ) has completed an IPO in the amount of SEK 52 million.

Elicera Therapeutics AB (publ) has completed an IPO in the amount of SEK 52 million.

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies